15787962 29273415 19807094 21761566 15999987 11543672 23016689 23200250 19430912 12477343 14991673 26491810 14711314 20560148 28464209 31397148 14754373 15491792 29107424 10612602 12672226 - Search Results

Year	Number of Results
1999	1
2001	1
2002	1
2003	2
2004	3
2005	2
2009	2
2011	2
2012	1
2013	2
2015	1
2017	3
2018	1
2019	1
2022	0

1

Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.

Bennett MA, Murray TF, Aldrich JV. Bennett MA, et al. J Pept Res. 2005 Mar;65(3):322-32. doi: 10.1111/j.1399-3011.2005.00216.x. J Pept Res. 2005. PMID: 15787962

2

Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).

Fang WJ, Murray TF, Aldrich JV. Fang WJ, et al. Bioorg Med Chem. 2018 Mar 15;26(6):1157-1161. doi: 10.1016/j.bmc.2017.11.029. Epub 2017 Nov 21. Bioorg Med Chem. 2018. PMID: 29273415 Free PMC article.

3

The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.

Patkar KA, Murray TF, Aldrich JV. Patkar KA, et al. J Med Chem. 2009 Nov 12;52(21):6814-21. doi: 10.1021/jm900715m. J Med Chem. 2009. PMID: 19807094 Free PMC article.

4

Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Aldrich JV, Kulkarni SS, Senadheera SN, Ross NC, Reilley KJ, Eans SO, Ganno ML, Murray TF, McLaughlin JP. Aldrich JV, et al. ChemMedChem. 2011 Sep 5;6(9):1739-45. doi: 10.1002/cmdc.201100113. Epub 2011 Jul 14. ChemMedChem. 2011. PMID: 21761566 Free PMC article.

5

[Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.

Patkar KA, Yan X, Murray TF, Aldrich JV. Patkar KA, et al. J Med Chem. 2005 Jul 14;48(14):4500-3. doi: 10.1021/jm050105i. J Med Chem. 2005. PMID: 15999987

6

[2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.

Lu Y, Nguyen TM, Weltrowska G, Berezowska I, Lemieux C, Chung NN, Schiller PW. Lu Y, et al. J Med Chem. 2001 Sep 13;44(19):3048-53. doi: 10.1021/jm0101186. J Med Chem. 2001. PMID: 11543672

7

Dynorphin convertases and their functions in CNS.

Ner J, Silberring J. Ner J, et al. Curr Pharm Des. 2013;19(6):1043-51. doi: 10.2174/1381612811319060006. Curr Pharm Des. 2013. PMID: 23016689 Review.

8

The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.

Nemoto T, Yamamoto N, Wada N, Harada Y, Tomatsu M, Ishihara M, Hirayama S, Iwai T, Fujii H, Nagase H. Nemoto T, et al. Bioorg Med Chem Lett. 2013 Jan 1;23(1):268-72. doi: 10.1016/j.bmcl.2012.10.100. Epub 2012 Oct 30. Bioorg Med Chem Lett. 2013. PMID: 23200250

9

Peptide kappa opioid receptor ligands: potential for drug development.

Aldrich JV, McLaughlin JP. Aldrich JV, et al. AAPS J. 2009 Jun;11(2):312-22. doi: 10.1208/s12248-009-9105-4. Epub 2009 May 9. AAPS J. 2009. PMID: 19430912 Free PMC article. Review.

10

Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist.

Bennett MA, Murray TF, Aldrich JV. Bennett MA, et al. J Med Chem. 2002 Dec 19;45(26):5617-9. doi: 10.1021/jm025575g. J Med Chem. 2002. PMID: 12477343

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results